VJHemOnc Podcast

Experts discuss the use of Treatment Free Interval Strategies in the Management of Multiple Myeloma, highlighting the importance of continuing therapy until progression and the association between continuation of therapy and superior progression free survival. This chapter discusses the concept of treatment free intervals in multiple myeloma, highlighting the drawbacks of continuous therapy and the potential benefits of allowing patients to have breaks from treatment. It emphasizes the importance of assessing minimum residual disease and considering outcomes beyond progression, such as quality of life and cost of therapy.

The podcast discusses the evolution of CLL management, including novel therapies and genetic markers. Topics include effective therapies, ongoing clinical trials, sequencing targeted therapies, and the relevance of prediction and prognostication markers. The chapter descriptions cover treatment options for higher risk CLL patients, treatment efficacy, and considerations for comorbidities.

Experts discuss the significance of MRD in shaping the future of multiple myeloma care, including intensifying or de-intensifying treatment based on MRD status, the ongoing debate on CAR-T approaches, and the potential uses of MRD in guiding treatment for myeloma.

Leading experts discuss the potential of CAR-T therapy and bi-specific antibodies as replacements for autologous stem cell transplantation in myeloma treatment. They explore their efficacy, dosing differences, immunogenicity, toxicity profiles, and patient outcomes. The role of ASCT in the future treatment of myeloma becomes a subject of debate.

Podcast discusses antibody therapies for non-Hodgkin lymphoma (NHL) with a focus on the use of antibody-drug conjugates, monoclonal antibodies, and bispecific antibodies. Topics include potential treatments for relapsed/refractory DLBCL, the effectiveness of glifitamab in B cell NHL, CD37 as a target for antibody drug conjugates, study findings on antibody drug and triplet combination therapy for lymphoma, and promising activity of triplet combination therapy for relapsed/refractory follicular lymphoma.

Novel therapies for AML are discussed, including anti-tim-3 antibody for MDS, durability of response in high-risk cohorts, and the effectiveness of guilt-written-em and IDH1 inhibitor. The use of Glazidinib and Lodo Cetarabin in combination for elderly AML patients is also explored.

The podcast discusses the latest updates on JAK inhibitors for MPNs and their impact on myelofibrosis patients, including potential benefits for symptomatic patients and the question of earlier use. It explores the efficacy and limitations of ruxolitinib as a treatment for MPNs, highlighting the need for alternative therapies. Additionally, it covers the potential approval of pacritinib for myelofibrosis and the long-term data on momelotinib, showcasing its consistent response in patients with splenic volume reduction and favorable safety and efficacy profiles.

This podcast discusses the latest clinical updates on targeted therapies for ALL, including CAR-T cell immunotherapy and the positive outcomes of the KTEX-19 trial. The ALMA protocol explores the use of targeted therapies and immunotherapy for ALL patients, highlighting promising results. The significance of minimal residual disease and the impact of the genetic landscape in ALL are also discussed.

Updates on interferons for the treatment of myeloproliferative neoplasms (MPNs), including results of clinical trials and the potential benefits of combining interferon with an agrolyte. Discussion on treatment options for young patients, including hydroxyurea and pegulated interferon, and consideration of quality of life. Exploration of a case series of pediatric and adolescent patients using interferon and the introduction of Ropech Interferon with its unique manufacturing process and administration method.

The podcast discusses the importance of real-world data in improving treatments for hematological malignancies. Topics covered include CAR-T therapy for large B cell lymphoma, treatment patterns and outcomes in multiple myeloma patients, effective treatment strategies for myeloma, lymphoma, and CLL, response rates and progression-free survival in multiple myeloma patients, and real-world data on CLL treatment and outcomes with ibrotin.